Precigen (I5X) Q2 2026 Earnings Report

The call conveyed strong commercial momentum for PAPZIMEOS driven by exceptional Q2 revenue growth (>145% QoQ), launch-to-date revenue >$78M, broad payer coverage (~315M lives), durable clinical responses (83% ongoing CR >3 years), and attainment of profitability for the quarter and first half of 2026. Operational and financial risks noted include normalization of gross margins after remaining prelaunch inventory is consumed, reliance on accounts receivable collections and existing debt interest expense, rising commercial and future R&D spend, and limited public granularity on exact account activation counts and non-hub patient visibility. Overall, the positive revenue, profitability, coverage, and durability developments materially outweigh the manageable operational and financial caveats.

Precigen guided that Q2 PAPZIMEOS revenue was $53.1M (Q1 $21.6M, >145% QoQ) and launch‑to‑date revenue exceeded $78M, with total Q2 revenues of $55M (COGS $2.8M; reported gross margin 95%); they expect gross margins to normalize to the high‑80% to low‑90% range after selling remaining pre‑approval inventory (anticipated in Q3). Financials/guidance included operating income of $22.6M, net income of $20.1M ($0.05/diluted), R&D $7.3M, SG&A $22.2M, cash and investments of $38.7M, trade receivables of $71.9M (expected to be collected over ~4 months), ~$100M debt with ~$3M quarterly interest (offset by ~ $0.4M interest income), and management’s view that cash + receivables will fund operations to cash‑flow breakeven by end‑2026. Commercial guidance/metrics: hub registrations >500, >200 patients have received ≥1 dose with >100 completing the 4‑dose course, ~315M covered lives after adding ~18M in Q2, permanent J‑code effective April 1, and 7‑year U.S. market exclusivity through August 2032.